mt-401-ots
·Code: MT-401-OTS
mt-401-ots: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Marker Therapeutics, Inc. (MRKR) | Phase 2 |
Clinical Trials (1)
A Phase 1 Study of Allogenic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cell Products (MT-401-OTS) Administered to Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes (RAPID)
Frequently asked questions
Who is developing mt-401-ots?
mt-401-ots is being developed by Marker Therapeutics, Inc..
How many clinical trials involve mt-401-ots?
BioSniper tracks 1 clinical trial involving mt-401-ots.
Get deeper analysis on mt-401-ots
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis